Printer Friendly

Macrocure completes patient enrolment in double-blind, Phase III clinical trial of CureXcell.

M2 PHARMA-September 4, 2014-Macrocure completes patient enrolment in double-blind, Phase III clinical trial of CureXcell

(C)2014 M2 COMMUNICATIONS

Macrocure, an Israel-based biotechnology company, has completed patient enrolment in its double-blind, Phase III clinical trial of CureXcell, it was reported yesterday.

The product is indicated to treat diabetic foot ulcers. It is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.

The company has enrolled and randomised a total of 280 patients at 25 sites in the Phase III trial. Presently, the producing is being assessed in two Phase III clinical trials to treat chronic, hard-to-heal wounds below the knee. The first trial is a multicentre, randomised, double-blind, parallel group, sham-controlled study of CureXcell in DFUs, and its results are likely to be reported in the second half of 2015. The firm's second Phase III clinical trial is assessing CureXcell in Venous Leg Ulcers, and interim data from the study is expected in the second half of 2015, with the trial scheduled to complete in the second half of 2016.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 4, 2014
Words:193
Previous Article:US subsidiary of Lundbeck launches Northera (droxidopa) capsules in US.
Next Article:BioLegend acquires Covance Antibody Services.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters